FOX04-DRI
FOXO4-DRI is a D-amino-acid peptide designed to disrupt FOXO4 and p53 binding in senescent cell research. Approved business buyers can apply for wholesale access.
US Peptide Distributors supplies FOX04-DRI at wholesale to approved business buyers. Every lot is tested by an independent third-party laboratory (we use Freedom Diagnostics and ILS Labs): HPLC for purity and mass spectrometry for identity. Pricing is quoted by supply option: USA stock, USA-synthesized or overseas-sourced, and USA stock offers same-day shipping with no minimum order.
Updated
- Synonyms
- FOXO4-DRI, FOXO4 D-retro-inverso peptide
- Formula
- C228H388N86O64
- Molecular weight
- 5358 g/mol
Approved buyers see pricing
Wholesale pricing is available to approved business buyers after they log in.
Supply and testing
- Every lot third-party testedHPLC for purity, mass spectrometry for identity. Labs: Freedom Diagnostics and ILS Labs.
- Three supply optionsSupply options for wholesale ordersUSA stock (ships from US inventory), USA-synthesized, overseas-sourced.Ask which options apply to this compound.
- Same-day shipping on USA stockExpedited options available. Overseas-sourced orders typically take 7-10 days.
- No minimum on USA stockOne box to thousands of kits, plus gram and kilogram powder.
- COA in your company nameCan be added to an order and is provided with it.
Distributor programShipping times
Request a quote for FOX04-DRINaming note
The product name is often typed "FOX04-DRI" with a zero, but the protein it is built around is FOXO4, with the letter O, a member of the forkhead box O transcription factor family. This page uses the product spelling in the title and the correct gene name in the text. Check that purchasing paperwork, labels and certificates use one spelling consistently, since records that differ by a character are hard to trace.
What the peptide is
FOXO4-DRI is a synthetic peptide of roughly 5.4 kDa. The PubChem record lists D-amino-acid residues throughout, rather than the L-forms of ordinary proteins. The 2025 NMR work describes it as containing a FOXO4-derived region plus a cationic cell-penetrating segment, and describes the whole molecule as disordered in solution. Such a molecule is quite unlike the small, well-folded peptides common in this catalogue.
The research question
Senescent cells are cells that have stopped dividing but persist and secrete inflammatory factors. A 2017 study in Cell identified FOXO4 as important to the survival of senescent cells and designed a peptide that perturbs its interaction with p53. In senescent cells the peptide caused p53 to leave the nucleus and triggered apoptosis. In mouse models, including fast-aging and naturally aged animals and mice given the chemotherapy drug doxorubicin, the authors reported differences in readouts such as fur density and renal function. That work is the origin of most of the subsequent interest.
Structural follow-up
Later papers examined the mechanism more closely. The 2025 Nature Communications study solved NMR structural models of the p53 transactivation domain bound to the FOXO4 forkhead domain and to FOXO4-DRI. It found that the disordered peptide binds the disordered p53 TAD2 region to form a transiently folded complex, with both the FOXO4-derived region and the cationic segment contributing, and that phosphorylation of p53 raises the affinity.
A second 2025 paper used NMR to map the hydrophobic contacts in the same interface and then designed an alternative peptide from L-amino acids, with fewer negative charges, which disrupted nuclear FOXO4-p53 foci and induced apoptosis in senescent cancer cells in culture. It is worth reading as a counterpoint, because it shows researchers trying to improve on the original design.
Sourcing notes
A peptide with this many charged residues is typically supplied as a salt, so mass-per-vial and peptide content differ. Our guide on purity, net content and counterions explains how to read that on a certificate.
Supply is for approved business buyers, for laboratory research use only.
References
- Baar MP, et al. Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging. Cell. 2017.
- Bourgeois B, et al. The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI. Nat Commun. 2025.
- Kang D, et al. Peptide Inhibitors Targeting FOXO4-p53 Interactions and Inducing Senescent Cancer Cell-specific Apoptosis. J Med Chem. 2025.
Questions
Where can I buy FOX04-DRI in bulk?
US Peptide Distributors supplies FOX04-DRI to approved business buyers. Apply for a buyer account to see wholesale pricing by supply option (USA stock, USA-synthesized or overseas-sourced). There is no minimum order on USA stock, and larger volumes are quoted on request.
Is FOX04-DRI sold for use in humans?
No. US Peptide Distributors sells FOX04-DRI to approved business buyers for laboratory research use only, not for use in humans.
Is each lot of FOX04-DRI third-party tested?
Yes. Every lot US Peptide Distributors supplies is tested by an independent third-party laboratory (we use Freedom Diagnostics and ILS Labs): HPLC for purity and mass spectrometry for identity. Lot COAs appear on this page as they are uploaded.